Share

    


In This Section

Home / About / Corporate Members / Educational Resources

Educational Resources

These educational resources, tools, and materials are brought to you by our valued Corporate Members. For questions or more information, please email CorporateRelations@accc-cancer.org for assistance.

  • Patient Education on Medicare Prescription Payment Plan

    Posted on 12/02/2024

    Bayer-Global-80x80





    HCP’s: Use these handouts to help patients understand their Medicare plan:
    English Version   Spanish Version



  • Desmoid Tumor ICD-10-CM Codes Flashcard

    Posted on 11/20/2024

    SpringWorks-275x80





    FDA-Approved Therapy and ICD-10-CM Codes for Desmoid Tumors. Desmoid tumors are rare, locally aggressive soft tissue tumors that are characterized by high rates of initial misdiagnosis.
    View Resource



  • 2025 Inflation Reduction Act (IRA) FRM

    Posted on 11/13/2024

    Pfizer-200x80



    Changes to Medicare Part D in 2025 will Cap Out-Of-Pocket (OOP) Costs for Patients. Please feel free to review & share this important resource.
    View Resource



  • Johnson and Johnson 2023 U.S. Pricing Transparency Report

    Posted on 11/09/2024

    Johnson-&-Johnson-460x80



    Johnson and Johnson’s eighth U.S. Pricing Transparency Report provides key data, analysis and insights that will help advance solutions to create a more sustainable, equitable and innovative healthcare system.
    View Resource



  • Anemia in Focus: The Challenge of Identifying Myelodysplastic Syndromes (MDS)

    Posted on 11/09/2024

    BMS-350x80


    Anemia is a hallmark of MDS, conferring heightened mortality risk and diminished quality of life. Please feel free to view & share this important resource.
    View Resource



  • Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups

    Posted on 11.11.2024

    Stemline-A-Menarini-Group-Company-320x90


    Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor–positive (ER+), HER2− metastatic breast cancer and tumors harboring estrogen receptor 1 (ESR1) mutation following ET plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i).
    View Resource



  • ADC Cast is a Non-Promotional Educational Podcast Series Dedicated to Antibody Drug Conjugates (ADCs) in Breast Cancer

    Posted on 10/16/2024

    Gilead-200x80.fw



    Hosted by Dr Javier Cortés and Prof. Peter Schmid, joined by an international panel of experts in ADCs and breast cancer, this educational podcast series unveils invaluable insights into ADCs, shedding light on their developmental history, their distinctive structural features and mechanisms of action, as well as potential future advancements.

    Posted on 10/16/2024

    Listen Here



  • Learn How LAG-3 Helps Tumors Evade the Immune System and Why Inhibiting It May Enhance Existing Immunotherapies

    Posted on 09.26.2024

    Labcorp-Oncology-578x80

    Could targeting LAG-3 take cancer immunotherapy to the next level? Dr. Sabi Pabla and Dr. Eric Severson share insights on this promising immune biomarker in the latest Labcorp Perspectives: Oncology interview.
    Listen Here



  • Small Moments Can Help You Spot Endometrial Cancer

    Posted on 08.12.2024

    Spot-Her-200x184


    Too often, women with endometrial cancer (EC) have reported that their symptoms were stigmatized and dismissed. Even though diagnoses and deaths from this type of uterine cancer are on the rise, EC remains under-recognized.

    Spot Her® is an initiative to help end the silence around EC and empower all people across generations and cultures to speak up, take action, and spot the potential signs at an early stage—when EC may be more treatable.
    Learn More



  • A Toolkit For Those Living With or Care For Someone with Diffuse Large B-Cell Lymphoma (DLBCL)

    Posted on 08.08.2024

    Incyte-386x260



    The purpose of this Toolkit is to help support your experience as someone living with Diffuse Large B-Cell Lymphoma (DLBCL) or as a care partner by providing information to help you build a deeper understanding of DLBCL. This Toolkit was created by a group of patients, care partners, advocates and healthcare professionals brought together by Incyte, a pharmaceutical company working on behalf of the DLBCL community.
    View Resource